Gilead Sciences: Hep-C Price War Takes Its Toll
February 04, 2015 at 10:13 AM EST
Shares of Gilead Sciences (GILD) are tumbling today following the release of its financial results last night–and it’s not because the numbers were bad. Associated Press Gilead said it earned $2.43 a share, besting forecasts for $2.16, on sales of $7.31 billion, topping the Street consensus for $6.67 billion. It also said it would buy back [...]
